“I’ve always believed in the power and potential of advanced AI to enrich human life and change our world. The work we’re doing here will help to realise that promise, and ultimately improve the lives of millions of people dealing with disease. I’m proud to be leading this amazing team and look forward to the progress we’ll make together.”
- Demis Hassabis
- Name of Company: Isomorphic Labs Limited
- Incorporation Date: February 4, 2021
- Founder: Demis Hassabis
- Origin of Idea: The company extends the work done at DeepMind, especially around the AlphaFold technology utilized for predicting protein structures essential for drug discovery.
- Funding: Isomorphic Labs is a subsidiary of Alphabet that was launched from Alphabet's DeepMind in 2021, with headquarters in London. Alphabet is the parent company of Google.
- More Information:
- Problem Being Solved: Isomorphic Labs aims to redefine and accelerate the drug discovery process using artificial intelligence.
- Intended Customer: Customers include pharmaceutical companies, research institutions, and healthcare providers involved in drug discovery and development.
- Unique Solutions: Isomorphic labs leverage AlphaFold technology for high accuracy in predicting protein structures, providing a foundation for identifying new pathways for drug delivery.
- Technologies Used: Primarily AlphaFold, developed by DeepMind, and enhancing and expanding upon this technology to extend its capabilities for drug discovery.
- More Information:
A detailed description of AlphaFold and its impact is provided in this YouTube video:
- Field: Drug Discovery, Biotechnology, Artificial Intelligence.
- Major Trends and Innovations (Last 5-10 years): The last decade and notably the last several years have seen integration of AI and machine learning in drug discovery and personalized medicine for predictive analysis and to reduce costs and to introduce novelty into an otherwise stagnating methods of doing things.
- Major Companies in Field: AI is significantly impacting drug discovery. Many of the large pharmaceutical companies e.g. GSK, Novartis, Amgen and Genentech are actively innovating in this space. Notable companies that have emerged in parallel to the current AI revolution include but are not limited to DeepMind, Insilico Medicine, Atomwise, Recursion Pharmaceuticals.
- Business Impact: Being a relatively new player, the business impact is not well-documented publicly, but their collaboration with DeepMind on AlphaFold 2 technology is significant towards accelerating drug discovery.
- Core Metrics for Success: Number of drug candidates identified, accuracy of predictions made by AI models, and the speed of new drug development.
- Performance Relative to Competitors: Not publicly available.
- Suggested Products/Services: Isomorphic lab is positioned to partner with other companies that have complementary strengths. Isomorphic labs will be able to provide knowledge on protein structure and protein complex structures that will expedite target engagement.
- Benefits of Suggested Offerings: The grand benefit is to increase the rate of pace of development of new medicines. Lifting the field and highlighting the utility of technology will be a consequence of accompanying any success.
- Technologies for Additional Products/Services: The latest update to AlphaFold can factor non-protein molecules such as small ligands and ions to enable more accurate prediction of structure.
- Appropriateness of Technologies: These technologies are at the forefront of biotech innovation, enabling more accurate analysis, predictions, and tailored solutions in drug discovery.